Craigavon, United Kingdom

Mark Peter Bell

USPTO Granted Patents = 1 

Average Co-Inventor Count = 14.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Mark Peter Bell: Innovator in Pharmaceutical Compounds

Introduction

Mark Peter Bell is a notable inventor based in Craigavon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target cancer treatment. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.

Latest Patents

Mark Peter Bell holds a patent for pharmaceutical compounds that act as inhibitors of the serine-threonine kinase AKT. This invention relates to a series of compounds with specific activity, which are crucial in the fight against cancer. The patent also includes pharmaceutical compositions that comprise these compounds, along with methods for treating cancer. He has 1 patent to his name, reflecting his commitment to innovation in the pharmaceutical industry.

Career Highlights

Mark is currently employed at Almac Discovery Limited, where he continues to work on groundbreaking research and development in pharmaceuticals. His role at the company allows him to collaborate with other talented professionals in the field, further enhancing his contributions to medical science.

Collaborations

Throughout his career, Mark has worked alongside esteemed colleagues such as Timothy Harrison and Sumita Bhattacharyya. These collaborations have played a vital role in the advancement of his research and the successful development of his patented compounds.

Conclusion

Mark Peter Bell is a distinguished inventor whose work in pharmaceutical compounds has the potential to make a significant impact on cancer treatment. His innovative spirit and dedication to research exemplify the importance of invention in the medical field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…